Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001202 | 1.00 | ALOX15 (0.46) | ALOX15KDM4EMEN1KMT2AMAPT | |
| SCHEMBL2169035 | 0.91 | KDM4E (0.52) | ALOX15KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7850983 | 0.91 | MEN1 (0.38) | ALOX15KDM4EMEN1KMT2AMAPT | |
| SCHEMBL14506392 | 0.91 | KDM4E (0.52) | ALOX15KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2250406 | 0.88 | MEN1 (0.48) | ALOX15KDM4EMEN1KMT2AMAPT | |
| SCHEMBL7679763 | 0.88 | ALOX15 (0.45) | ALOX15KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22473770 | 0.87 | ALOX15 (0.45) | ALOX15KDM4EMEN1KMT2AMAPT | |
| SCHEMBL7672799 | 0.87 | ALOX15 (0.47) | ALOX15KDM4EMEN1KMT2AMAPT | |
| SCHEMBL2381406 | 0.87 | ALOX15 (0.47) | ALOX15KDM4EMEN1KMT2AMAPT | |
| SCHEMBL7859587 | 0.86 | NPC1 (0.44) | ALOX15KDM4EMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | JUNO THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250381272-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | JUNO THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250242020-A1 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1) | JUNO THERAPEUTICS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | JUNO THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-12268741-B2 | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) | JUNO THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12263190-B2 | Methods and combinations for treatment and T cell modulation | JUNO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20050214328-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders | CELGENE CORPORATION | 2005-09-29 | — | — | US | disclosed |
| WO-2005065455-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CELGENE CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143420-A1 | administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione | SIGNAL PHARMACEUTICALS, LLC | 2005-06-30 | — | — | US | disclosed |
| US-20050143344-A1 | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases | CELGENE CORPORATION | 2005-06-30 | — | — | US | disclosed |
| WO-2005055929-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND MANAGEMENT OF HEMOGLOBINOPATHY AND ANEMIA | CELGENE CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-05-12 | — | — | US | disclosed |
| US-6380239-B1 | FOR THERAPY OF ARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, REPERFUSION INJURY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHREMATOSIS, SCLERODERMA, APHTHOUS ULCERS, ASTHMA | CELGENE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| CN-1342146-A | Substituted 1-oxo-and 1, 3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels | CELGENE CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1163219-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055134-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | ALOX15 2222/4885KDM4E 352/4885MEN1 2429/4885 |
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CA13, CA12, CA14 | ALOX15 2679/4885KDM4E 2250/4885MEN1 235/4885 |
| US-20250242020-A1 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1) | ROR1, RORB, RORC | ALOX15 4456/4885KDM4E 3978/4885MEN1 4334/4885 |
| US-12268741-B2 | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) | ROR1, RORB, RORC | ALOX15 4456/4885KDM4E 3978/4885MEN1 4334/4885 |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | ICOS, MDM2, XIAP | ALOX15 3451/4885KDM4E 821/4885MEN1 3533/4885 |
| US-20050143344-A1 | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases | SMN1; SMN2, GBA1, AQP4 | ALOX15 552/4885KDM4E 3601/4885MEN1 3743/4885 |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | CD4, CD2, ICOS | ALOX15 2606/4885KDM4E 2844/4885MEN1 4011/4885 |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | MALT1, BCL9, ICOS | ALOX15 4188/4885KDM4E 658/4885MEN1 1711/4885 |
| US-20250381272-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | BCL6, BCL3, PBK | ALOX15 2706/4885KDM4E 1387/4885MEN1 3333/4885 |
| US-20050214328-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders | MMP1, SSB, MMP8 | ALOX15 647/4885KDM4E 1389/4885MEN1 2702/4885 |
| US-20050143420-A1 | administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione | HBG1, HBG2, CD47 | ALOX15 2347/4885KDM4E 2655/4885MEN1 4684/4885 |
| US-12263190-B2 | Methods and combinations for treatment and T cell modulation | ICOS, MDM2, XIAP | ALOX15 3451/4885KDM4E 821/4885MEN1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.